Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
March 31, 2021
The Biostage (BSTG) Chronicles: could not complete the filing of its Form 10-K for the period ended 12/31/2020
March 28, 2021
The Biostage (BSTG) Chronicles … the questions continued
March 23, 2021
Solid Biosciences (SLDB) closed 25 million share offering at $5.75
March 13, 2021
Biostage (BSTG): WHO, WHAT, WHEN, WHERE and WHY?
March 13, 2021
WHO, WHAT, WHEN, WHERE and WHY? Reiterating …
March 10, 2021
WHO, WHAT, WHEN, WHERE and WHY
March 10, 2021
WHO, WHAT, WHEN, WHERE and WHY
February 22, 2021
BrainStorm Cell Therapeutics (BCLI) slammed by FDA for the “Lack of Substantial Data for Submission”
February 21, 2021
It Will Take The G-7 To Stop Covid-19: Here Are 5 Reasons Why
February 17, 2021
Caladrius Biosciences (CLBS) closes $65 M RDO (registered direct offering)
February 9, 2021
Biostage (BSTG): the questions linger … for there are never any answers from the company?
February 2, 2021
Pluristem (PSTI) proposes 4.76 M Registered Direct Offering (RDO) priced at $6.30
January 28, 2021
Bellicum Pharmaceuticals (BLCM) FDA has lifted the clinical hold
January 28, 2021
Applied Genetic Technologies (AGTC) prices 16.741 M share offering and warrants at $4.45
January 26, 2021
Precigen (PGEN) closes 17.25 M share offering at $7.50
January 25, 2021
Caladrius Biosciences (CLBS) closes $25 M Private Placement of 12.5 M shares plus warrants at a purchase price of $2.00
January 19, 2021
Editas Medicine (EDIT) proposes 3.5 million shares offering
January 12, 2021
REGENXBIO (RGNX) closes 4.26 million share offering at $47.00
January 6, 2021
Fate Therapeutics (FATE) prices 4.42 million share offering at $85.50 per share
December 15, 2020
Cellectis S.A. (CLLS) cancels $100 M ADS (American Depositary Shares) offering
December 11, 2020
Solid Biosciences (SLDB) executes a $90 M Private Placement
December 2, 2020
Intellia Therapeutics (NTLA) prices 4.79 million share offering at $36.50
November 4, 2020
Bellicum Pharmaceuticals (BLCM) closes 1.04 M share offering
August 12, 2020
Adverum Biotechnologies (ADVM) closes $216.8 million offering priced at $3.00
July 8, 2020
BioLife Solutions (BLFS) closes 5.95 million share offering priced at $14.50
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2022 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.